☆ 4.7 Article

Anti-Claudin18.2-IL-21 fusion protein bifunctional molecule has more powerful anti-tumor effect and better safety

INTERNATIONAL IMMUNOPHARMACOLOGY (2023)

Related references

Note: Only part of the references are listed.

Review Oncology

Harnessing cytokines and chemokines for cancer therapy

David J. Propper et al.

Summary: Cytokines play a crucial role in cancer development and progression. While cytokines have been studied for their therapeutic potential in oncology, clinical trials have shown limited efficacy. However, the advent of immunotherapies and a better understanding of the tumor microenvironment have opened up new possibilities for harnessing cytokine networks in cancer treatment.

NATURE REVIEWS CLINICAL ONCOLOGY (2022)

Add to Collection

Article Immunology

A tumor-specific pro-IL-12 activates preexisting cytotoxic T cells to control established tumors

Diyuan Xue et al.

Summary: A tumor-conditional IL-12, pro-IL-12, was developed to selectively activate TILs and control tumor growth with reduced toxicity. Pro-IL-12 improved the efficacy of immune checkpoint blockade and targeted therapy when used in combination.

SCIENCE IMMUNOLOGY (2022)

Add to Collection

Article Immunology

Novel insights in CAR-NK cells beyond CAR-T cell technology; promising advantages

Hamidreza Ebrahimiyan et al.

Summary: CAR-NK cells offer a promising alternative to CAR-T cell therapy in cancer immunotherapy. They have advantages such as lack of side effects, GvHD, and diverse cell sources, making CAR-NK therapy more feasible.

INTERNATIONAL IMMUNOPHARMACOLOGY (2022)

Add to Collection

Article Immunology

Development of a Humanized VHH Based Recombinant Antibody Targeting Claudin 18.2 Positive Cancers

Weixiang Zhong et al.

Summary: This study has successfully developed a potential therapeutic candidate targeting CLDN18.2, a protein frequently over-expressed in gastric and pancreatic cancers. The candidate demonstrated desirable binding specificity and efficacy in in vitro and in vivo experiments, making it a promising agent for CLDN18.2 positive cancers.

FRONTIERS IN IMMUNOLOGY (2022)

Add to Collection

Article Immunology

Design and Characterization of Novel Antibody-Cytokine Fusion Proteins Based on Interleukin-21

Cesare Di Nitto et al.

Summary: This study describes four formats of IL21-based antibody-cytokine fusion proteins and explores their potential for cancer treatment. One of the fusion proteins showed promising characteristics in vitro and in vivo. However, further improvement is required for tumor targeting.

ANTIBODIES (2022)

Add to Collection

Review Oncology

The dawn of precision medicine in diffuse-type gastric cancer

Akira Ooki et al.

Summary: Gastric cancer is a common malignancy with distinct subtypes. Diffuse-type gastric cancer (DGC) is aggressive and has limited response to systemic chemotherapy. CLDN18.2 and FGFR2-IIIb have been identified as potential therapeutic targets for DGC, and recent clinical trials have shown promising results with anti-CLDN18.2 and FGFR2-IIIb antibodies.

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2022)

Add to Collection

Review Immunology

Engineering IL-2 for immunotherapy of autoimmunity and cancer

Rosmely Hernandez et al.

Summary: IL-2, the first approved immunotherapy for cancer treatment, not only promotes immunity but also regulates tolerance through regulatory T cells. The crystal structure of IL-2 bound to its receptor has paved the way for the development of engineered IL-2 products.

NATURE REVIEWS IMMUNOLOGY (2022)

Add to Collection

Article Immunology

An engineered IL-21 with half-life extension enhances anti-tumor immunity as a monotherapy or in combination with PD-1 or TIGIT blockade

Hongchuan Liu et al.

Summary: The fusion protein IL-21-alpha HSA demonstrated enhanced stability and prolonged half-life, resulting in significant anti-tumor efficacy. When used in combination with immune checkpoint blockades, it enhanced the cytotoxic activity of CD8(+) T and NK cells, leading to a long-term anti-tumor memory response.

INTERNATIONAL IMMUNOPHARMACOLOGY (2021)

Add to Collection

Article Oncology

FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma

U. Sahin et al.

Summary: This study demonstrates that adding zolbetuximab to first-line EOX treatment in advanced gastric cancer patients expressing CLDN18.2 can provide longer progression-free survival (PFS) and overall survival (OS). The therapy is generally well-tolerated with manageable adverse events.

ANNALS OF ONCOLOGY (2021)

Add to Collection

Article Oncology

Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

Hyuna Sung et al.

Summary: The global cancer burden in 2020 saw an estimated 19.3 million new cancer cases and almost 10.0 million cancer deaths. Female breast cancer surpassed lung cancer as the most commonly diagnosed cancer, while lung cancer remained the leading cause of cancer death. These trends are expected to rise in 2040, with transitioning countries experiencing a larger increase compared to transitioned countries due to demographic changes and risk factors associated with globalization and a growing economy. Efforts to improve cancer prevention measures and provision of cancer care in transitioning countries will be crucial for global cancer control.

CA-A CANCER JOURNAL FOR CLINICIANS (2021)

Add to Collection

Review Immunology

Biological effects of IL-15 on immune cells and its potential for the treatment of cancer

Shuling Zhang et al.

Summary: IL-15 has emerged as a novel immunomodulatory cytokine in cancer immunotherapy, with the potential to reject and destroy cancer cells by expanding and activating immune cells. Preclinical studies and clinical trials have shown promising outcomes, suggesting a possible future clinical application of IL-15-based therapy in combination with other treatments. Understanding the biological characteristics of IL-15 is crucial for maximizing therapeutic benefits.

INTERNATIONAL IMMUNOPHARMACOLOGY (2021)

Add to Collection

Article Multidisciplinary Sciences

Targeting IL-21 to tumor-reactive T cells enhances memory T cell responses and anti-PD-1 antibody therapy

Ying Li et al.

Summary: The study demonstrates that fusion of IL-21 to anti-PD-1 antibody can enhance T cell activity and promote T cell rejuvenation, leading to improved anti-tumor effects. This potential strategy shows promise in targeting cytokines to tumor-reactive T cells to enhance the therapeutic effects of immune checkpoint blockade.

NATURE COMMUNICATIONS (2021)

Add to Collection

Article Oncology

Patient-reported outcomes from the phase II FAST trial of zolbetuximab plus EOX compared to EOX alone as first-line treatment of patients with metastatic CLDN18.2+gastroesophageal adenocarcinoma

Florian Lordick et al.

Summary: The ZOL/EOX combination in the FAST trial showed better patient-reported outcomes in terms of quality of life and symptom burden compared to EOX alone, especially during maintenance therapy.

GASTRIC CANCER (2021)

Add to Collection

Article Cell Biology

The Half-Life-Extended IL21 can Be Combined With Multiple Checkpoint Inhibitors for Tumor Immunotherapy

Shaoxian Wu et al.

Summary: The study shows that prolonged half-life IL21 combined with PD-1 blockade therapy can enhance the effector function of type 1 lymphocytes, inhibit the growth of mouse tumors, increase the fraction of DC1 and M1 macrophages in the tumor microenvironment, but also induce immune regulatory mechanisms.

FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2021)

Add to Collection

Review Oncology

Cytokines in the Treatment of Melanoma

Salah-Eddine Bentebibel et al.

Summary: This review discusses the use of cytokines in harnessing the immune system to eradicate cancer, focusing on their basic biology and therapeutic applications in the treatment of melanoma. It also highlights innovative technological approaches to improve the pharmacokinetics, safety, and efficacy of these cytokines. Recent findings show promising results in clinical trials for newly engineered cytokines, suggesting potential for greater clinical benefits in the future.

CURRENT ONCOLOGY REPORTS (2021)

Add to Collection

Article Cell Biology

Immunoengineering approaches for cytokine therapy

Aslan Mansurov et al.

Summary: Efforts to achieve therapeutic translation of cytokines for treating diseases such as cancer and autoimmune diseases have been hindered by the unfavorable pharmacokinetic and pharmacodynamic profiles of wild-type cytokines, leading to challenging toxicity profiles and limited therapeutic efficacy. Further research and development in protein-engineering approaches are needed to address these limitations and enhance the therapeutic indices of cytokines for more effective treatment.

AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY (2021)

Add to Collection

Article Cell Biology

Tumor-conditional IL-15 pro-cytokine reactivates anti-tumor immunity with limited toxicity

Jingya Guo et al.

Summary: A next-generation IL-15 cytokine has been developed in this study, which can be activated inside the tumor microenvironment without causing systemic toxicity by avoiding peripheral expansion of NK and T cells. The anti-tumor effect of pro-IL-15 depends on intratumoral CD8(+) T cells and IFN-gamma, and it helps overcome immune checkpoint blockade resistance and synergizes with current targeted-therapy. This novel IL-15 cytokine shows potent anti-tumor activity while minimizing severe toxicity.

CELL RESEARCH (2021)

Add to Collection

Article Pharmacology & Pharmacy

Selection and Characterization of FD164, a High-Affinity Signal Regulatory Protein α Variant with Balanced Safety and Effectiveness, from a Targeted Epitope Mammalian Cell-Displayed Antibody Library

Zhihong Wang et al.

Summary: Phagocytic resistance is crucial in tumor immune escape, with CD47 being a key immune checkpoint. In this study, an engineered SIRP alpha variant Fc fusion protein, FD164, with higher CD47-binding affinity, was developed, showing promising potential for cancer treatment with improved phagocytic effects and tumor suppression activities. The discovery of FD164 provides a reference for the development of effective and safe anti-tumor drugs targeting CD47.

MOLECULAR PHARMACOLOGY (2021)

Add to Collection

Article Engineering, Multidisciplinary

High-Affinity Decoy PD-1 Mutant Screened from an Epitope-Specific Cell Library

Hao Liu et al.

Summary: Immunotherapy targeting the PD-1/PD-L1 pathway has become a standard treatment for various types of human cancers. This study identified a decoy PD-1 mutant, 463, with significantly increased affinity to PD-L1 and demonstrated inhibitory effects against PD-1, showing potential as a promising option for PD-1/PD-L1-related cancers.

ENGINEERING (2021)

Add to Collection

Review Biochemistry & Molecular Biology

Biological bases of cancer immunotherapy

Maryanne M. Gonzales Carazas et al.

Summary: Immunotherapy has made significant strides in cancer treatment, although challenges such as high cost, resistance, and variability of responses persist. The search for better predictive biomarkers shows promise in addressing these obstacles.

EXPERT REVIEWS IN MOLECULAR MEDICINE (2021)

Add to Collection

Review Oncology

CAR-NK for tumor immunotherapy: Clinical transformation and future prospects

Wenxiu Wang et al.

CANCER LETTERS (2020)

Add to Collection

Article Immunology

Engineered IL-21 Cytokine Muteins Fused to Anti-PD-1 Antibodies Can Improve CD8+T Cell Function and Anti-tumor Immunity

Shanling Shen et al.

FRONTIERS IN IMMUNOLOGY (2020)

Add to Collection

Article Oncology

Prognostic impact of Claudin 18.2 in gastric and esophageal adenocarcinomas

A. Arnold et al.

CLINICAL & TRANSLATIONAL ONCOLOGY (2020)

Add to Collection

Review Oncology

The drug treatment research of gastrointestinal cancer in China

Chao Ren et al.

EJSO (2020)

Add to Collection

Editorial Material Medicine, General & Internal

Immune checkpoint inhibitors in cancer immunotherapy

Megan E. Himmel et al.

CANADIAN MEDICAL ASSOCIATION JOURNAL (2020)

Add to Collection

Editorial Material Cell Biology

IL-18: throwing off the shackles to boost anti-tumor immunity

Karen O. Dixon et al.

CELL RESEARCH (2020)

Add to Collection

Article Biochemistry & Molecular Biology

Cytokines in the Treatment of Cancer

Kevin C. Conlon et al.

JOURNAL OF INTERFERON AND CYTOKINE RESEARCH (2019)

Add to Collection

Article Oncology

Claudin18.2-Specific Chimeric Antigen Receptor Engineered T Cells for the Treatment of Gastric Cancer

Hua Jiang et al.

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2019)

Add to Collection

Article Oncology

Claudin18.2-Specific Chimeric Antigen Receptor Engineered T Cells for the Treatment of Gastric Cancer

Hua Jiang et al.

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2019)

Add to Collection

Article Oncology

A multicentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower oesophagus: the MONO study

O. Tuereci et al.

ANNALS OF ONCOLOGY (2019)

Add to Collection

Review Oncology

Cytokines in clinical cancer immunotherapy

Pedro Berraondo et al.

BRITISH JOURNAL OF CANCER (2019)

Add to Collection

Review Biotechnology & Applied Microbiology

Delivery technologies for cancer immunotherapy

Rachel S. Riley et al.

NATURE REVIEWS DRUG DISCOVERY (2019)

Add to Collection

Article Oncology

Characterization of zolbetuximab in pancreatic cancer models

Oezlem Tuereci et al.

ONCOIMMUNOLOGY (2019)

Add to Collection

Article Immunology

Selection and characterization of the novel anti-human PD-1 FV78 antibody from a targeted epitope mammalian cell-displayed antibody library

Longlong Luo et al.

CELLULAR & MOLECULAR IMMUNOLOGY (2018)

Add to Collection

Article Cell Biology

The Common Cytokine Receptor. Chain Family of Cytokines

Jian-Xin Lin et al.

COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY (2018)

Add to Collection

Article Oncology

A phase I dose-escalation study of IMAB362 (Zolbetuximab) in patients with advanced gastric and gastro-oesophageal junction cancer

Ugur Sahin et al.

EUROPEAN JOURNAL OF CANCER (2018)

Add to Collection

Review Oncology

Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations

Jun Gong et al.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)

Add to Collection

Review Oncology

Anti-claudin 18.2 antibody as new targeted therapy for advanced gastric cancer

Prabhsimranjot Singh et al.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2017)

Add to Collection

Article Hematology

Anti-CD20-interleukin-21 fusokine targets malignant B cells via direct apoptosis and NK-cell-dependent cytotoxicity

Shruti Bhatt et al.

BLOOD (2017)

Add to Collection

Article Oncology

Antibody Improves Survival in Gastric Cancer

Cancer Discovery (2016)

Add to Collection

Article Oncology

Claudin 18.2 is a target for IMAB362 antibody in pancreatic neoplasms

Stefan Woell et al.

INTERNATIONAL JOURNAL OF CANCER (2014)

Add to Collection

Article Oncology

Aberrantly activated claudin 6 and 18.2 as potential therapy targets in non-small-cell lung cancer

Patrick Micke et al.

INTERNATIONAL JOURNAL OF CANCER (2014)

Add to Collection

Article

Immunotherapy of melanoma

John B.A.G. Haanen

EJC SUPPLEMENTS (2013)

Add to Collection

Article Pharmacology & Pharmacy

Preclinical Safety, Pharmacokinetics, and Pharmacodynamics of Recombinant Human Interleukin-21 in Cynomolgus Macaques (Macaca fascicularis)

Kimberly S. Waggie et al.

INTERNATIONAL JOURNAL OF TOXICOLOGY (2012)

Add to Collection

Article Medicine, Research & Experimental

Generation and characterization of human anti-human IL-21 neutralizing monoclonal antibodies

Mark F. Maurer et al.

MABS (2012)

Add to Collection

Review Biotechnology & Applied Microbiology

Interleukin-21: updated review of Phase I and II clinical trials in metastatic renal cell carcinoma, metastatic melanoma and relapsed/refractory indolent non-Hodgkin's lymphoma

Mehmood H. Hashmi et al.

EXPERT OPINION ON BIOLOGICAL THERAPY (2010)

Add to Collection

© Peeref 2019-2024. All rights reserved.